CN102198251A - 一种治疗更年期综合征的中药组合物及其制备方法 - Google Patents
一种治疗更年期综合征的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN102198251A CN102198251A CN 201110131213 CN201110131213A CN102198251A CN 102198251 A CN102198251 A CN 102198251A CN 201110131213 CN201110131213 CN 201110131213 CN 201110131213 A CN201110131213 A CN 201110131213A CN 102198251 A CN102198251 A CN 102198251A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- preparation
- chinese medicinal
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 241000005787 Cistanche Species 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 241001237431 Anomala Species 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- -1 filtered Substances 0.000 claims description 3
- 241000407170 Curcuma Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 8
- 241000411851 herbal medicine Species 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 206010060800 Hot flush Diseases 0.000 description 12
- 210000001672 ovary Anatomy 0.000 description 12
- 239000008187 granular material Substances 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 9
- 102000009151 Luteinizing Hormone Human genes 0.000 description 9
- 108010073521 Luteinizing Hormone Proteins 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 229960005309 estradiol Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 4
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003818 cinder Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013360 fish flour Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101312134A CN102198251B (zh) | 2011-05-19 | 2011-05-19 | 一种治疗更年期综合征的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101312134A CN102198251B (zh) | 2011-05-19 | 2011-05-19 | 一种治疗更年期综合征的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102198251A true CN102198251A (zh) | 2011-09-28 |
CN102198251B CN102198251B (zh) | 2012-08-08 |
Family
ID=44659406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101312134A Active CN102198251B (zh) | 2011-05-19 | 2011-05-19 | 一种治疗更年期综合征的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102198251B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755521A (zh) * | 2012-07-31 | 2012-10-31 | 施慧达药业集团(吉林)有限公司 | 一种用于治疗更年期综合症的中药制剂及其制备方法 |
CN104888176A (zh) * | 2015-06-29 | 2015-09-09 | 孙小荣 | 一种治疗脾肾阳虚型更年期综合症的中药 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1868530A (zh) * | 2005-05-27 | 2006-11-29 | 广州中医药大学第二附属医院 | 一种治疗乳腺增生病的中药组合物及其制备方法 |
CN101919963A (zh) * | 2010-08-02 | 2010-12-22 | 靳照礼 | 一种中药组合物及其制备方法和应用 |
-
2011
- 2011-05-19 CN CN2011101312134A patent/CN102198251B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1868530A (zh) * | 2005-05-27 | 2006-11-29 | 广州中医药大学第二附属医院 | 一种治疗乳腺增生病的中药组合物及其制备方法 |
CN101919963A (zh) * | 2010-08-02 | 2010-12-22 | 靳照礼 | 一种中药组合物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
《云南中医中药杂志》 20080420 班胜等 无排卵性不孕症中医药治疗进展 52-54 1-3 第29卷, 第04期 * |
《浙江中医杂志》 20110216 贝润浦 卵巢切除后再生案 133-134 1-3 第46卷, 第02期 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102755521A (zh) * | 2012-07-31 | 2012-10-31 | 施慧达药业集团(吉林)有限公司 | 一种用于治疗更年期综合症的中药制剂及其制备方法 |
CN102755521B (zh) * | 2012-07-31 | 2014-01-29 | 施慧达药业集团(吉林)有限公司 | 一种用于治疗更年期综合症的中药制剂及其制备方法 |
CN104888176A (zh) * | 2015-06-29 | 2015-09-09 | 孙小荣 | 一种治疗脾肾阳虚型更年期综合症的中药 |
Also Published As
Publication number | Publication date |
---|---|
CN102198251B (zh) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1329065C (zh) | 一种治疗妇女更年期综合症的药物及其制备方法 | |
CN100402081C (zh) | 治疗妇科疾病的中成药及其制备方法 | |
CN1857690A (zh) | 妇科病制剂及新的制备方法 | |
CN100496585C (zh) | 一种治疗黄褐斑的中药制剂 | |
CN101269170B (zh) | 一种治疗更年期综合征的药物及其制备方法 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN104689226A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN101507776B (zh) | 一种治疗肾虚、腰膝酸软的中药制剂及其制备方法 | |
CN102988675B (zh) | 一种治疗慢性前列腺炎的中药组合物及其制备方法 | |
CN104983916B (zh) | 具有增强免疫力及延缓衰老的保健品及其制备方法与应用 | |
CN104288228A (zh) | 一种治疗颈肩腰腿痛的中药组合物 | |
CN101537159B (zh) | 一种中药组合物及其制备方法和应用 | |
CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
CN102198251B (zh) | 一种治疗更年期综合征的中药组合物及其制备方法 | |
CN105796845A (zh) | 药物组合物在制备治疗女性更年期综合征药物中的用途 | |
CN102343019B (zh) | 一种用于治疗闭经的中药组合物及其制剂的制备方法 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN104888157A (zh) | 一种治疗子宫肌瘤的中药制剂及其制备方法 | |
CN105944020B (zh) | 一种治疗卵巢功能下降的中药 | |
CN104189349A (zh) | 一种治疗月经量少的中药组合物 | |
CN103919961B (zh) | 一种治疗中老年肾亏肾阳虚的中药制剂及其制备方法 | |
CN112451608A (zh) | 一种具有“骨肾同治”效应的补肾温阳通络方 | |
CN104162090B (zh) | 一种药物组合物及其制备方法 | |
CN116421675B (zh) | 一种用于治疗非酒精性脂肪性肝病的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200421 Address after: 300385 E63, No.1, Sizhi Road, Xuefu Industrial Zone, Xiqing District, Tianjin Patentee after: INCREASE (TIANJIN) INNOVATIVE MEDICINE RESEARCH Co.,Ltd. Address before: 130012, 155, pioneering street, hi tech Zone, Jilin, Changchun Patentee before: Wang Lishu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231215 Address after: Room 1-507, 5th Floor, Building 1, No. 1588 Shanghai Hangzhou Road, Fengxian District, Shanghai, 2014 Patentee after: Shanghai Dinghui Pharmaceutical Co.,Ltd. Address before: 300385 E63, No. 1, Sizhi Road, Xuefu Industrial Zone, Xiqing District, Tianjin Patentee before: INCREASE (TIANJIN) INNOVATIVE MEDICINE RESEARCH Co.,Ltd. |
|
TR01 | Transfer of patent right |